Biocon eyes Canadian bonanza from generics of weight-loss 'super-drugs' Ozempic and Wegovy

Biocon Ltd. is set to seek regulatory approvals for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting key markets like Canada, where patents expire next year. Managing Director Siddharth Mittal sees Canada as a prime opportunity, aiming for potential approval in 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SAtE7h3
via IFTTT

0 comments:

Post a Comment